by Portfolio Grader | October 23, 2013 11:45 am
The grades of six Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Mirati Therapeutics Inc. (NASDAQ:MRTX) is seeing ratings go up from a C last week to a B this week. Mirati Therapeutics engages in the development of therapeutics for the treatment of cancer. For more information, get Portfolio Grader’s complete analysis of MRTX stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shows solid improvement this week. The company’s rating rises from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This is a strong week for Array BioPharma (NASDAQ:ARRY). The company’s rating climbs to B from the previous week’s C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This week, Insmed Incorporated (NASDAQ:INSM) pushes up from a C to a B rating. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/10/6-biotechnology-stocks-to-buy-now-aria-mrtx-nbix/
Short URL: http://invstplc.com/1nArzvx
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.